Charles River Laboratories International, INC Form 4 insider transactions

Joseph W. LaPlume, EVP at Charles River Laboratories, disposed of shares to cover tax obligations related to vested stock.

Birgit Girshick, Corporate Executive VP & COO of Charles River Laboratories, reported the disposal of common stock to cover tax obligations.

Director George Massaro of Charles River Laboratories sold a portion of his common stock holdings on May 15, 2024, under a pre-arranged 10b5-1 trading plan.

Director Virginia Wilson reported acquiring common stock and stock options in Charles River Laboratories on May 13, 2024.

Director Nancy C. Andrews acquired common stock and stock options in Charles River Laboratories on May 13, 2024.

Director Martin Mackay acquired common stock and stock options in Charles River Laboratories International, Inc. on May 13, 2024.

Director Craig B. Thompson acquired 559 shares of common stock and 1,311 stock options in Charles River Laboratories on May 13, 2024.

Director Richard F. Wallman reports acquisition of common stock and stock options in Charles River Laboratories.

Robert J. Bertolini, a director at Charles River Laboratories, recently acquired common stock and stock options in the company.

Director Reshema Kemps-Polanco reports acquiring common stock and stock options in Charles River Laboratories International, Inc.

Director George Llado Sr. reports acquisition of common stock and stock options in Charles River Laboratories.

George Massaro, a director at Charles River Laboratories, recently acquired shares and stock options in the company.

Director Deborah Turner Kochevar reports acquisition of common stock and stock options in Charles River Laboratories.

Joseph W. LaPlume, EVP at Charles River Laboratories, sold 1,304 shares of common stock on May 10, 2024.

Flavia Pease, Corporate Executive VP & CFO of Charles River Laboratories, reported disposing of 893 shares of common stock on May 2, 2024.

Victoria Creamer, EVP & Chief People Officer at Charles River Laboratories, reports the acquisition and disposal of company stock.

James C. Foster, Chairman, President, and CEO of Charles River Laboratories, filed an amendment to his Form 4, detailing transactions involving the company's common stock.

Shannon M. Parisotto, CEVP at Charles River Laboratories, reports transactions involving common stock, including acquisitions and disposals, following the achievement of performance goals.

Corporate Executive VP & CCO William D. Barbo reports acquisition and disposal of Charles River Laboratories International, Inc. stock following the achievement of performance goals.

Joseph W. LaPlume, EVP at Charles River Laboratories, reports acquisition and disposal of common stock following performance share unit vesting.

Birgit Girshick, Corporate Executive VP & COO of Charles River Laboratories, reports acquisition and disposal of common stock related to performance share unit awards.

Michael Knell, CSVP & Chief Accounting Officer of Charles River Laboratories, reports acquisition and disposal of company stock.

Michael Gunnar Knell, CSVP & Chief Accounting Officer of Charles River Laboratories, sold 808 shares of common stock on March 8, 2024.

Michael Gunnar Knell, CSVP & Chief Accounting Officer of Charles River Laboratories, sold a total of 2,750 shares of common stock on March 4, 2024.

Shannon M. Parisotto, CEVP at Charles River Laboratories, reports selling shares and receiving a share transfer.

Victoria L. Creamer, EVP & Chief People Officer of Charles River Laboratories International, Inc., sold 5,000 shares of common stock on February 29, 2024.